Fundamental and Clinical Studies of Cefotaxime in Mature and Premature Infants: A Study of Cefotaxime by the Perinatal Co-research Group

Ryochi Fujii; Shintaro Hashira; Yoriko Koike; Masatoshi Takimoto; Toshiaki Oka; Hajime Yoshioka; Nobutaka Sanae; Shizuo Maruyama; Seiichiro Nanri; Hironobu Akita; Keiji Jozaki; Satoshi Iwata; Yukio Iwasaki; Masahiro Tojo; Masahiro Hotta; Naoya Yamashita; Keisuke Sunakawa; Tadao Oikawa; Mitsuru Osano; Yasuo Ichihashi; Kazuo Ishikawa; Takefumi Kanemitsu; Shiei Ri; Kensuke Shirane; Kozo Kanki; Shioko Kawai; Nobuo Saito; Susumu Nakazawa; Hajime Sato; Yuichx Hirama; Hidejiro Chikaoka; Yoshikiyo Toyonaga; Yoshiie Kurosu; Morimasa Sugita; Makoto Hori; Naoichi Iwai; Akira Sasaki; Yōichi Taneda; Fumiko Mizoguchi; Haruhi Nakamura; Tadafumi Nishimura; Toshio Takashima; Kenji Hiromatsu; Kazuo Tabuki; Yutaka Kobayashi; Yutaka Kobayashi; Tsunekazu Haruta; Kanetsu Okura; Shigekazu Kuroki; Toru Fujiwara; Kazumi Goto; Takashi Motohiro; Kōichi Tanaka; Tatsuhiko Koga; Yasushi Shimada; Naofumi Tomita; Yasutaka Sakata; Tamotsu Fujimoto; Tohru Nishiyama; Tetsuya Nakajima; Kōji Ishimoto; Kaoru Tominaga; Fumio Yamashita; Nobuhiko Takajō; Hisaaki Araki; Shōichi Imai; Takeshi Yuasa; Yoshimi Tanaka; Shin Tsugawa; Kiyotaka Nagayama; Takeo Hashimoto; Hirofumi Nakajima; Hiroshi Matsuo; Fusae Imuta; Jiro Yura; Nobuatsu Tsuruga; Syusaku Hayashi; Yukitaka Murata

doi:10.11250/chemotherapy1953.31.309

Fundamental and Clinical Studies of Cefotaxime in Mature and Premature Infants: A Study of Cefotaxime by the Perinatal Co-research Group

Ryochi Fujii, Shintaro Hashira, Yoriko Koike, Masatoshi Takimoto, Toshiaki Oka, Hajime Yoshioka, Nobutaka Sanae, Shizuo Maruyama, Seiichiro Nanri, Hironobu Akita, Keiji Jozaki, Satoshi Iwata, Yukio Iwasaki, Masahiro Tojo, Masahiro Hotta, Naoya Yamashita, Keisuke Sunakawa, Tadao Oikawa, Mitsuru Osano, Yasuo IchihashiKazuo Ishikawa, Takefumi Kanemitsu, Shiei Ri, Kensuke Shirane, Kozo Kanki, Shioko Kawai, Nobuo Saito, Susumu Nakazawa, Hajime Sato, Yuichx Hirama, Hidejiro Chikaoka, Yoshikiyo Toyonaga, Yoshiie Kurosu, Morimasa Sugita, Makoto Hori, Naoichi Iwai, Akira Sasaki, Yōichi Taneda, Fumiko Mizoguchi, Haruhi Nakamura, Tadafumi Nishimura, Toshio Takashima, Kenji Hiromatsu, Kazuo Tabuki, Yutaka Kobayashi, Yutaka Kobayashi, Tsunekazu Haruta, Kanetsu Okura, Shigekazu Kuroki, Toru Fujiwara, Kazumi Goto, Takashi Motohiro, Kōichi Tanaka, Tatsuhiko Koga, Yasushi Shimada, Naofumi Tomita, Yasutaka Sakata, Tamotsu Fujimoto, Tohru Nishiyama, Tetsuya Nakajima, Kōji Ishimoto, Kaoru Tominaga, Fumio Yamashita, Nobuhiko Takajō, Hisaaki Araki, Shōichi Imai, Takeshi Yuasa, Yoshimi Tanaka, Shin Tsugawa, Kiyotaka Nagayama, Takeo Hashimoto, Hirofumi Nakajima, Hiroshi Matsuo, Fusae Imuta, Jiro Yura, Nobuatsu Tsuruga, Syusaku Hayashi, Yukitaka Murata

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Cefotaxime is a new semisynthetic cephalosporin displaying high antibacterial activity against grampositive, gram-negative and anaerobic organisms. It acts bactericidally and is stable against betalactamases. The authors investigated the usefulness of cefotaxime in the treatment of infections in mature and premature infants and the following results were obtained; The half-life of cefotaxime after i. v. administration in mature and premature infants was inversely related to age, and tended to be longer in the former than the latter although there were pronounced intersubject differences. The pharmacokinetics of cefotaxime after i. v. injection of 10 mg/kg and 20 mg/kg was dose-related. The half-life of cefotaxime after i. v. drip infusion revealed a same trend after i. v. injection. Urinary concentration and urinary recovery were directly related. Cefotaxime was effective in 92. 5% of 80 patients, consisting of 61 mature and 19 premature infants. Responder rates by the main indications treated were 100% in 19 cases of meningitis, 81.8% in 11 cases of septicemia, 88. 0% in 25 cases of respiratory tract infection, 100% in 5 cases of urinary tract infection, 100% in 3 cases of SSS syndrome, and 100% in 4 cases of phlegmon. Forty-six pathogens were isolated from 38 patients. Excluding 4 strains for which the bacteriological response was inassessable, the eradication rate against the remaining 42 strains was 78. 6%. All 6 strains of Group B Streptococcus were isolated from patients with meningitis. Cefotaxime was both clinically and bacteriologically effective in all of these cases. Cefotaxime was effective in 20 (90.9%) of 22 patients with infections refractory to other antibiotics. Diarrhea, skin rash, elevations of GOT, GPT and LDH, and leukopenia were noted in several cases, but none of these adverse reactions were problematic. Diarrhea and skin rash occurred mainly in nursing infants. Fundamental and clinical studies of cefotaxime were carried out in mature and premature infants requiring antibiotic treatment. Cefotaxime was demonstrated to be a useful antibiotic for the treatment of infections in neonates.

Original language	English
Pages (from-to)	309-323
Number of pages	15
Journal	Chemotherapy
Volume	31
Issue number	3
DOIs	https://doi.org/10.11250/chemotherapy1953.31.309
Publication status	Published - 1983 Jan
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.31.309

Cite this

Fujii, R., Hashira, S., Koike, Y., Takimoto, M., Oka, T., Yoshioka, H., Sanae, N., Maruyama, S., Nanri, S., Akita, H., Jozaki, K., Iwata, S., Iwasaki, Y., Tojo, M., Hotta, M., Yamashita, N., Sunakawa, K., Oikawa, T., Osano, M., ... Murata, Y. (1983). Fundamental and Clinical Studies of Cefotaxime in Mature and Premature Infants: A Study of Cefotaxime by the Perinatal Co-research Group. Chemotherapy, 31(3), 309-323. https://doi.org/10.11250/chemotherapy1953.31.309

Fujii, R, Hashira, S, Koike, Y, Takimoto, M, Oka, T, Yoshioka, H, Sanae, N, Maruyama, S, Nanri, S, Akita, H, Jozaki, K, Iwata, S, Iwasaki, Y, Tojo, M, Hotta, M, Yamashita, N, Sunakawa, K, Oikawa, T, Osano, M, Ichihashi, Y, Ishikawa, K, Kanemitsu, T, Ri, S, Shirane, K, Kanki, K, Kawai, S, Saito, N, Nakazawa, S, Sato, H, Hirama, Y, Chikaoka, H, Toyonaga, Y, Kurosu, Y, Sugita, M, Hori, M, Iwai, N, Sasaki, A, Taneda, Y, Mizoguchi, F, Nakamura, H, Nishimura, T, Takashima, T, Hiromatsu, K, Tabuki, K, Kobayashi, Y, Kobayashi, Y, Haruta, T, Okura, K, Kuroki, S, Fujiwara, T, Goto, K, Motohiro, T, Tanaka, K, Koga, T, Shimada, Y, Tomita, N, Sakata, Y, Fujimoto, T, Nishiyama, T, Nakajima, T, Ishimoto, K, Tominaga, K, Yamashita, F, Takajō, N, Araki, H, Imai, S, Yuasa, T, Tanaka, Y, Tsugawa, S, Nagayama, K, Hashimoto, T, Nakajima, H, Matsuo, H, Imuta, F, Yura, J, Tsuruga, N, Hayashi, S & Murata, Y 1983, 'Fundamental and Clinical Studies of Cefotaxime in Mature and Premature Infants: A Study of Cefotaxime by the Perinatal Co-research Group', Chemotherapy, vol. 31, no. 3, pp. 309-323. https://doi.org/10.11250/chemotherapy1953.31.309

@article{1df411007afc46709b91dae6d8b3087c,

title = "Fundamental and Clinical Studies of Cefotaxime in Mature and Premature Infants: A Study of Cefotaxime by the Perinatal Co-research Group",

abstract = "Cefotaxime is a new semisynthetic cephalosporin displaying high antibacterial activity against grampositive, gram-negative and anaerobic organisms. It acts bactericidally and is stable against betalactamases. The authors investigated the usefulness of cefotaxime in the treatment of infections in mature and premature infants and the following results were obtained; The half-life of cefotaxime after i. v. administration in mature and premature infants was inversely related to age, and tended to be longer in the former than the latter although there were pronounced intersubject differences. The pharmacokinetics of cefotaxime after i. v. injection of 10 mg/kg and 20 mg/kg was dose-related. The half-life of cefotaxime after i. v. drip infusion revealed a same trend after i. v. injection. Urinary concentration and urinary recovery were directly related. Cefotaxime was effective in 92. 5% of 80 patients, consisting of 61 mature and 19 premature infants. Responder rates by the main indications treated were 100% in 19 cases of meningitis, 81.8% in 11 cases of septicemia, 88. 0% in 25 cases of respiratory tract infection, 100% in 5 cases of urinary tract infection, 100% in 3 cases of SSS syndrome, and 100% in 4 cases of phlegmon. Forty-six pathogens were isolated from 38 patients. Excluding 4 strains for which the bacteriological response was inassessable, the eradication rate against the remaining 42 strains was 78. 6%. All 6 strains of Group B Streptococcus were isolated from patients with meningitis. Cefotaxime was both clinically and bacteriologically effective in all of these cases. Cefotaxime was effective in 20 (90.9%) of 22 patients with infections refractory to other antibiotics. Diarrhea, skin rash, elevations of GOT, GPT and LDH, and leukopenia were noted in several cases, but none of these adverse reactions were problematic. Diarrhea and skin rash occurred mainly in nursing infants. Fundamental and clinical studies of cefotaxime were carried out in mature and premature infants requiring antibiotic treatment. Cefotaxime was demonstrated to be a useful antibiotic for the treatment of infections in neonates.",

author = "Ryochi Fujii and Shintaro Hashira and Yoriko Koike and Masatoshi Takimoto and Toshiaki Oka and Hajime Yoshioka and Nobutaka Sanae and Shizuo Maruyama and Seiichiro Nanri and Hironobu Akita and Keiji Jozaki and Satoshi Iwata and Yukio Iwasaki and Masahiro Tojo and Masahiro Hotta and Naoya Yamashita and Keisuke Sunakawa and Tadao Oikawa and Mitsuru Osano and Yasuo Ichihashi and Kazuo Ishikawa and Takefumi Kanemitsu and Shiei Ri and Kensuke Shirane and Kozo Kanki and Shioko Kawai and Nobuo Saito and Susumu Nakazawa and Hajime Sato and Yuichx Hirama and Hidejiro Chikaoka and Yoshikiyo Toyonaga and Yoshiie Kurosu and Morimasa Sugita and Makoto Hori and Naoichi Iwai and Akira Sasaki and Yōichi Taneda and Fumiko Mizoguchi and Haruhi Nakamura and Tadafumi Nishimura and Toshio Takashima and Kenji Hiromatsu and Kazuo Tabuki and Yutaka Kobayashi and Yutaka Kobayashi and Tsunekazu Haruta and Kanetsu Okura and Shigekazu Kuroki and Toru Fujiwara and Kazumi Goto and Takashi Motohiro and Kōichi Tanaka and Tatsuhiko Koga and Yasushi Shimada and Naofumi Tomita and Yasutaka Sakata and Tamotsu Fujimoto and Tohru Nishiyama and Tetsuya Nakajima and Kōji Ishimoto and Kaoru Tominaga and Fumio Yamashita and Nobuhiko Takajō and Hisaaki Araki and Shōichi Imai and Takeshi Yuasa and Yoshimi Tanaka and Shin Tsugawa and Kiyotaka Nagayama and Takeo Hashimoto and Hirofumi Nakajima and Hiroshi Matsuo and Fusae Imuta and Jiro Yura and Nobuatsu Tsuruga and Syusaku Hayashi and Yukitaka Murata",

year = "1983",

month = jan,

doi = "10.11250/chemotherapy1953.31.309",

language = "English",

volume = "31",

pages = "309--323",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "3",

}

TY - JOUR

T1 - Fundamental and Clinical Studies of Cefotaxime in Mature and Premature Infants

T2 - A Study of Cefotaxime by the Perinatal Co-research Group

AU - Fujii, Ryochi

AU - Hashira, Shintaro

AU - Koike, Yoriko

AU - Takimoto, Masatoshi

AU - Oka, Toshiaki

AU - Yoshioka, Hajime

AU - Sanae, Nobutaka

AU - Maruyama, Shizuo

AU - Nanri, Seiichiro

AU - Akita, Hironobu

AU - Jozaki, Keiji

AU - Iwata, Satoshi

AU - Iwasaki, Yukio

AU - Tojo, Masahiro

AU - Hotta, Masahiro

AU - Yamashita, Naoya

AU - Sunakawa, Keisuke

AU - Oikawa, Tadao

AU - Osano, Mitsuru

AU - Ichihashi, Yasuo

AU - Ishikawa, Kazuo

AU - Kanemitsu, Takefumi

AU - Ri, Shiei

AU - Shirane, Kensuke

AU - Kanki, Kozo

AU - Kawai, Shioko

AU - Saito, Nobuo

AU - Nakazawa, Susumu

AU - Sato, Hajime

AU - Hirama, Yuichx

AU - Chikaoka, Hidejiro

AU - Toyonaga, Yoshikiyo

AU - Kurosu, Yoshiie

AU - Sugita, Morimasa

AU - Hori, Makoto

AU - Iwai, Naoichi

AU - Sasaki, Akira

AU - Taneda, Yōichi

AU - Mizoguchi, Fumiko

AU - Nakamura, Haruhi

AU - Nishimura, Tadafumi

AU - Takashima, Toshio

AU - Hiromatsu, Kenji

AU - Tabuki, Kazuo

AU - Kobayashi, Yutaka

AU - Haruta, Tsunekazu

AU - Okura, Kanetsu

AU - Kuroki, Shigekazu

AU - Fujiwara, Toru

AU - Goto, Kazumi

AU - Motohiro, Takashi

AU - Tanaka, Kōichi

AU - Koga, Tatsuhiko

AU - Shimada, Yasushi

AU - Tomita, Naofumi

AU - Sakata, Yasutaka

AU - Fujimoto, Tamotsu

AU - Nishiyama, Tohru

AU - Nakajima, Tetsuya

AU - Ishimoto, Kōji

AU - Tominaga, Kaoru

AU - Yamashita, Fumio

AU - Takajō, Nobuhiko

AU - Araki, Hisaaki

AU - Imai, Shōichi

AU - Yuasa, Takeshi

AU - Tanaka, Yoshimi

AU - Tsugawa, Shin

AU - Nagayama, Kiyotaka

AU - Hashimoto, Takeo

AU - Nakajima, Hirofumi

AU - Matsuo, Hiroshi

AU - Imuta, Fusae

AU - Yura, Jiro

AU - Tsuruga, Nobuatsu

AU - Hayashi, Syusaku

AU - Murata, Yukitaka

PY - 1983/1

Y1 - 1983/1

N2 - Cefotaxime is a new semisynthetic cephalosporin displaying high antibacterial activity against grampositive, gram-negative and anaerobic organisms. It acts bactericidally and is stable against betalactamases. The authors investigated the usefulness of cefotaxime in the treatment of infections in mature and premature infants and the following results were obtained; The half-life of cefotaxime after i. v. administration in mature and premature infants was inversely related to age, and tended to be longer in the former than the latter although there were pronounced intersubject differences. The pharmacokinetics of cefotaxime after i. v. injection of 10 mg/kg and 20 mg/kg was dose-related. The half-life of cefotaxime after i. v. drip infusion revealed a same trend after i. v. injection. Urinary concentration and urinary recovery were directly related. Cefotaxime was effective in 92. 5% of 80 patients, consisting of 61 mature and 19 premature infants. Responder rates by the main indications treated were 100% in 19 cases of meningitis, 81.8% in 11 cases of septicemia, 88. 0% in 25 cases of respiratory tract infection, 100% in 5 cases of urinary tract infection, 100% in 3 cases of SSS syndrome, and 100% in 4 cases of phlegmon. Forty-six pathogens were isolated from 38 patients. Excluding 4 strains for which the bacteriological response was inassessable, the eradication rate against the remaining 42 strains was 78. 6%. All 6 strains of Group B Streptococcus were isolated from patients with meningitis. Cefotaxime was both clinically and bacteriologically effective in all of these cases. Cefotaxime was effective in 20 (90.9%) of 22 patients with infections refractory to other antibiotics. Diarrhea, skin rash, elevations of GOT, GPT and LDH, and leukopenia were noted in several cases, but none of these adverse reactions were problematic. Diarrhea and skin rash occurred mainly in nursing infants. Fundamental and clinical studies of cefotaxime were carried out in mature and premature infants requiring antibiotic treatment. Cefotaxime was demonstrated to be a useful antibiotic for the treatment of infections in neonates.

AB - Cefotaxime is a new semisynthetic cephalosporin displaying high antibacterial activity against grampositive, gram-negative and anaerobic organisms. It acts bactericidally and is stable against betalactamases. The authors investigated the usefulness of cefotaxime in the treatment of infections in mature and premature infants and the following results were obtained; The half-life of cefotaxime after i. v. administration in mature and premature infants was inversely related to age, and tended to be longer in the former than the latter although there were pronounced intersubject differences. The pharmacokinetics of cefotaxime after i. v. injection of 10 mg/kg and 20 mg/kg was dose-related. The half-life of cefotaxime after i. v. drip infusion revealed a same trend after i. v. injection. Urinary concentration and urinary recovery were directly related. Cefotaxime was effective in 92. 5% of 80 patients, consisting of 61 mature and 19 premature infants. Responder rates by the main indications treated were 100% in 19 cases of meningitis, 81.8% in 11 cases of septicemia, 88. 0% in 25 cases of respiratory tract infection, 100% in 5 cases of urinary tract infection, 100% in 3 cases of SSS syndrome, and 100% in 4 cases of phlegmon. Forty-six pathogens were isolated from 38 patients. Excluding 4 strains for which the bacteriological response was inassessable, the eradication rate against the remaining 42 strains was 78. 6%. All 6 strains of Group B Streptococcus were isolated from patients with meningitis. Cefotaxime was both clinically and bacteriologically effective in all of these cases. Cefotaxime was effective in 20 (90.9%) of 22 patients with infections refractory to other antibiotics. Diarrhea, skin rash, elevations of GOT, GPT and LDH, and leukopenia were noted in several cases, but none of these adverse reactions were problematic. Diarrhea and skin rash occurred mainly in nursing infants. Fundamental and clinical studies of cefotaxime were carried out in mature and premature infants requiring antibiotic treatment. Cefotaxime was demonstrated to be a useful antibiotic for the treatment of infections in neonates.

UR - http://www.scopus.com/inward/record.url?scp=0020628566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020628566&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.31.309

DO - 10.11250/chemotherapy1953.31.309

M3 - Article

AN - SCOPUS:0020628566

SN - 0009-3165

VL - 31

SP - 309

EP - 323

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

IS - 3

ER -

Fundamental and Clinical Studies of Cefotaxime in Mature and Premature Infants: A Study of Cefotaxime by the Perinatal Co-research Group

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this